信号转导和转录激活因子6通过调控铁死亡介导脓毒症小鼠骨骼肌细胞损伤
研究将24只8周龄雄性SPF级昆明小鼠随机分为正常对照组、假手术组、脓毒症模型组和STAT6抑制剂预处理组,每组6只,以盲肠结扎穿孔(CLP)复制脓毒症模型,STAT6抑制剂组于造模前1小时腹腔注射AS1517499 10 mg/kg。造模后24小时取材,HE染色及透射电镜观察骨骼肌组织与线粒体形态,Western blotting检测铁死亡标志蛋白CHI3L1、COX-2、ACSL4、FTH1和GPx4。结果模型组骨骼肌结构疏松、肌纤维萎缩、炎性细胞浸润甚至肌纤维丢失,线粒体变小、膜密度增高、嵴减少或消失、外膜破裂;STAT6抑制剂预处理组上述组织与超微结构损伤明显改善,CHI3L1、COX-2、ACSL4、FTH1蛋白表达显著降低,GPx4蛋白表达显著升高(均P < 0.05)。作者认为STAT6可能通过调控COX-2、ACSL4、FTH1和GPx4表达介导小鼠骨骼肌细胞铁死亡,从而参与脓毒症骨骼肌细胞损伤。
要点
- 脓毒症模型组骨骼肌CHI3L1、COX-2、ACSL4、FTH1蛋白表达较正常对照和假手术组显著升高,GPx4显著降低,提示骨骼肌细胞发生铁死亡。
- STAT6抑制剂AS1517499 10 mg/kg于造模前1小时腹腔注射预处理,可显著降低脓毒症小鼠骨骼肌CHI3L1、COX-2、ACSL4、FTH1蛋白表达并升高GPx4(均P < 0.05)。
- STAT6抑制剂预处理组骨骼肌组织结构紧密、骨骼肌萎缩改善,电镜下肌细胞超微结构较模型组明显改善。
- 模型组电镜可见细胞膜破裂起疱、线粒体变小膜密度增高、线粒体嵴减少或消失、线粒体外膜破裂等铁死亡相关超微结构特征。
- 作者认为STAT6可能通过调控COX-2、ACSL4、FTH1和GPx4表达介导小鼠骨骼肌细胞铁死亡,进而诱导脓毒症骨骼肌细胞损伤。
适用人群与场景
- 8周龄雄性SPF级昆明小鼠,共24只,随机分为正常对照组、假手术组、脓毒症模型组和STAT6抑制剂预处理组,每组6只。
- 脓毒症模型采用盲肠结扎穿孔(CLP)复制;假手术组仅暴露盲肠组织后缝合皮肤。
诊断标准与关键阈值
- 铁死亡判定依据:骨骼肌CHI3L1、COX-2、ACSL4、FTH1蛋白表达升高,GPx4蛋白表达降低,并伴特征性线粒体损伤(线粒体变小、膜密度增高、嵴减少或消失、外膜破裂)。
处置流程与药物剂量
- STAT6抑制剂预处理组于造模前1小时腹腔注射AS1517499 10 mg/kg;假手术组和模型组腹腔注射等体积生理盐水;正常对照组不做任何手术或药物干预。
- 造模后24小时处死小鼠,无菌条件取后肢肌肉组织,HE染色光镜观察组织病理,醋酸铀-柠檬酸铅双染色后透射电镜观察线粒体形态,Western blotting检测CHI3L1、COX-2、ACSL4、FTH1和GPx4蛋白表达。
研究设计与关键结果
- 光镜下正常对照组和假手术组骨骼肌形态结构正常;模型组骨骼肌结构疏松、肌纤维变小萎缩、炎性细胞浸润甚至肌纤维丢失;STAT6抑制剂预处理组较模型组结构紧密、骨骼肌萎缩改善。
- 透射电镜下正常对照组和假手术组骨骼肌细胞超微结构正常;模型组细胞膜破裂起疱、线粒体变小且膜密度增高、线粒体嵴减少或消失、线粒体外膜破裂,细胞核大小正常但缺乏染色质凝聚;STAT6抑制剂预处理组肌细胞超微结构较模型组明显改善。
- 与正常对照组和假手术组比较,模型组骨骼肌CHI3L1、COX-2、ACSL4和FTH1蛋白表达显著升高,GPx4蛋白表达显著降低。
- 与模型组比较,STAT6抑制剂预处理组CHI3L1蛋白(CHI3L1/GAPDH)0.70±0.08 vs. 0.97±0.09、COX-2蛋白(COX-2/GAPDH)0.61±0.03 vs. 0.83±0.03、ACSL4蛋白(ACSL4/GAPDH)0.75±0.04 vs. 1.02±0.16、FTH1蛋白(FTH1/GAPDH)0.49±0.06 vs. 0.76±0.13均显著降低(均P < 0.05)。
- 与模型组比较,STAT6抑制剂预处理组GPx4蛋白表达显著升高(GPx4/GAPDH:1.14±0.29 vs. 0.53±0.03,P < 0.05)。
证据类型、等级与局限
- 证据类型:动物实验(小鼠脓毒症模型),24只8周龄雄性SPF级昆明小鼠,每组6只。
- 局限:原文未报告局限性。
对床旁实践的改变
- 该研究为小鼠实验,作者认为STAT6可能通过调控COX-2、ACSL4、FTH1和GPx4表达介导小鼠骨骼肌细胞铁死亡,从而诱导脓毒症骨骼肌细胞损伤;尚不能直接转化为急诊或ICU床旁决策。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To explore the effect of signal transducer and activator of transcription 6 (STAT6) on ferroptosis in skeletal muscle cells in sepsis model and its potential mechanism.
METHODS: Twenty-four 8-week-old male specific pathogen free Kunming mice were divided into normal control group, sham group, sepsis model group and STAT6 inhibitor pretreatment group according to random number table method with 6 mice in each group. A mouse sepsis model was reproduced by cecal ligation and perforation (CLP). In the sham group, the skin of mice was sutured after exposing the cecum tissue. In the STAT6 inhibitor pretreatment group, 10 mg/kg AS1517499 was injected intraperitoneally 1 hour before model reproduction. The sham group and the model group were intraperitoneally injected with the same volume of normal saline. Mice in the normal control group did not receive any operation or drug intervention. The mice were sacrificed 24 hours after model reproduction, and the muscle tissue of hind limb was obtained under sterile condition. Hematoxylin-eosin (HE) staining was used to observe the histopathology with optical microscope, and mitochondrial morphological changes were observed by transmission electron microscopy after double staining with uranium acetate lead citrate. The ferroptosis marker proteins expressions of chitinase-3-like protein 1 (CHI3L1), cyclooxygenase-2 (COX-2), acyl-CoA synthetase long-chain family member 4 (ACSL4), ferritin heavy chain 1 (FTH1), and glutathione peroxidase 4 (GPx4) were detected by Western blotting.
RESULTS: Under the optical microscope, the morphology and structure of skeletal muscle tissues in the normal control and sham groups were normal. In the model group, the structure of skeletal muscle tissues was loose, the muscle fiber became smaller and atrophic, inflammatory cell infiltration and even muscle fiber loss were found. Compared with the model group, the structure of skeletal muscle tissues was tight and skeletal muscle atrophy was improved in the STAT6 inhibitor pretreatment group. The ultrastructure of skeletal muscle cell in the normal control and sham groups was normal under transmission electron microscope. The ultrastructure characteristics of skeletal muscle in the model group showed that cell membrane was broken and blister, mitochondria became smaller and membrane density increased, the mitochondrial crista decreased or disappeared, the mitochondrial outer membrane was broken, and the nucleus was normal in size but lacked chromatin condensation. Compared with the model group, the STAT6 inhibitor pretreatment group had a significant improvement in the ultrastructure of muscle cells. Compared with the normal control and sham groups, the protein expressions of CHI3L1, COX-2, ACSL4 and FTH1 in the muscle of the model group were significantly increased, while the protein expression of GPx4 was decreased significantly, indicating that the skeletal muscle cells in the mouse sepsis model showed characteristic mitochondrial injury and abnormal expression of ferroptosis markers. Compared with the model group, the protein expressions of CHI3LI, COX-2, ACSL4 and FTH1 in the STAT6 inhibitor pretreatment group were significantly decreased [CHI3L1 protein (CHI3L1/GAPDH): 0.70±0.08 vs. 0.97±0.09, COX-2 protein (COX-2/GAPDH): 0.61±0.03 vs. 0.83±0.03, ACSL4 protein (ACSL4/GAPDH): 0.75±0.04 vs. 1.02±0.16, FTH1 protein (FTH1/GAPDH): 0.49±0.06 vs. 0.76±0.13, all P < 0.05], while the protein expression of GPx4 was significantly increased (GPx4/GAPDH: 1.14±0.29 vs. 0.53±0.03, P < 0.05).
CONCLUSIONS: Sepsis can induce ferroptosis in skeletal muscle cells of mice. STAT6 may mediate ferroptosis in mouse skeletal muscle cells by regulating the expressions of COX-2, ACSL4, FTH1 and GPx4, thereby inducing skeletal muscle cell injury in sepsis.
参考来源
- Li F, Wang S, Zhou Y, et al. [Signal transducer and activator of transcription 6 mediates skeletal muscle cell injury in septic mice by regulating ferroptosis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2023. PMID: 37593858. doi:10.3760/cma.j.cn121430-20230312-00170
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。